Business Insider
Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory ...
Nasdaq
Journey Medical Reports Pooled Phase 3 Data For Emrosi In Rosacea
(RTTNews) - Journey Medical Corporation (DERM) on Thursday presented pooled Phase 3 data from MVOR-1 and MVOR-2 evaluating DFD-29 (Emrosi) — 40 mg Minocycline Hydrochloride Modified-Release Capsules — ...